MedPath

Naproxen

Generic Name
Naproxen
Brand Names
Aleve, Aleve PM, Aleve-D, Anaprox, Naprelan, Naprosyn, Sallus, Sudafed Sinus & Pain, Treximet, Vimovo
Drug Type
Small Molecule
Chemical Formula
C14H14O3
CAS Number
22204-53-1
Unique Ingredient Identifier
57Y76R9ATQ

Overview

Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.

Background

Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.

Indication

Naproxen is indicated for the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain. Further, it is first-line therapy for osteoarthritis, acute gouty arthritis, dysmenorrhea, and musculoskeletal inflammation and pain.

Associated Conditions

  • Acute Gouty Arthritis
  • Acute Migraine
  • Ankylosing Spondylitis (AS)
  • Back pain
  • Bursitis
  • Extra-Articular Rheumatism
  • Fever
  • Flu caused by Influenza
  • Headache
  • Juvenile Idiopathic Arthritis (JIA)
  • Menstrual Distress (Dysmenorrhea)
  • Migraine
  • Muscle Spasms
  • Nasal Congestion
  • Osteoarthritis (OA)
  • Pain
  • Post Traumatic Pain
  • Postoperative pain
  • Primary Dysmenorrhoea
  • Rheumatoid Arthritis
  • Rheumatoid Arthritis, Juvenile
  • Seasonal Allergic Rhinitis
  • Sinusitis
  • Tendinitis
  • Toothache
  • Articular inflammation

FDA Approved Products

Naproxen
Manufacturer:Glenmark Pharmaceuticals Inc., USA
Route:ORAL
Strength:250 mg in 1 1
Approved: 2021/05/31
NDC:68462-188
Naproxen
Manufacturer:Glenmark Pharmaceuticals Inc., USA
Route:ORAL
Strength:375 mg in 1 1
Approved: 2021/05/31
NDC:68462-189
Naproxen
Manufacturer:QPharma, Inc.
Route:ORAL
Strength:500 mg in 1 1
Approved: 2023/08/18
NDC:42708-043
Naproxen
Manufacturer:Unit Dose Services
Route:ORAL
Strength:250 mg in 1 1
Approved: 2016/05/31
NDC:50436-0188
Naproxen
Manufacturer:Unit Dose Services
Route:ORAL
Strength:500 mg in 1 1
Approved: 2016/05/31
NDC:50436-0190

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath